As per reports, Brazil’s National Health Surveillance Agency (Anvisa) approved the Butantan-DV dengue vaccine for individuals aged 12 to 59 years on Wednesday (26 November).
• The single-dose vaccine, developed by the Butantan Institute, is reported to have an efficacy of 79.60 percent against the disease and 91.60 percent against its most severe form.
• The Brazilian Health Ministry has an agreement with Chinese firm WuXi for the supply of approximately 30 million doses, expected in the second half of 2026.
• This approval is expected to facilitate and accelerate future public mass vaccination campaigns against dengue.
